Bioceres Crop Solutions Corp.
BIOX
$11.97
-$0.08-0.66%
| Weiss Ratings | BIOX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Good | |||
| Risk Index | Fair | |||
| Risk Grade | C- | |||
| Reward Grade | B | |||
| Rating Factors | BIOX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Excellent | |||
| Efficiency Index | Fair | |||
| Solvency Index | Good | |||
| Total Return Index | Fair | |||
| Volatility Index | Fair | |||
| Beta / Standard Deviation | BIOX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.68 | |||
| Price History | BIOX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -1.77% | |||
| 30-Day Total Return | -4.53% | |||
| 60-Day Total Return | -8.39% | |||
| 90-Day Total Return | -9.54% | |||
| Year to Date Total Return | -10.21% | |||
| 1-Year Total Return | 12.51% | |||
| 2-Year Total Return | 7.37% | |||
| 3-Year Total Return | -12.08% | |||
| 5-Year Total Return | 181.15% | |||
| 52-Week High % Change | -14.93% | |||
| 52-Week Low % Change | 23.77% | |||
| Price | BIOX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $14.20 | |||
| 52-Week Low Price | $9.76 | |||
| 52-Week Low Price (Date) | May 09, 2023 | |||
| 52-Week High Price (Date) | Jun 23, 2023 | |||
| Valuation | BIOX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 761.48M | |||
| Enterprise Value | 991.39M | |||
| Price/Earnings (TTM) | 34.90 | |||
| Earnings Per Share (TTM) | 0.35 | |||
| Earnings Per Share Growth | -188.73% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 1.70 | |||
| Price/Book (Q) | 2.53 | |||
| Enterprise Value/Revenue (TTM) | 2.18 | |||
| Price | $12.23 | |||
| Enterprise Value/EBITDA (TTM) | 14.47 | |||
| Enterprise Value/EBIT | 18.58 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | BIOX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 63.88M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | BIOX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 54 34 1486 1100 | |||
| Address | -- | |||
| Website | biocerescrops.com | |||
| Country | Argentina | |||
| Year Founded | 2001 | |||
| Profitability | BIOX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 11.71% | |||
| Profit Margin | 4.83% | |||
| Management Effectiveness | BIOX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 3.93% | |||
| Return on Equity | 7.24% | |||
| Income Statement | BIOX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 454.53M | |||
| Total Revenue (TTM) | 454.53M | |||
| Revenue Per Share | $7.12 | |||
| Gross Profit (TTM) | 188.03M | |||
| EBITDA (TTM) | 68.36M | |||
| EBIT (TTM) | 53.23M | |||
| Net Income (TTM) | 21.96M | |||
| Net Income Avl. to Common (TTM) | 21.96M | |||
| Total Revenue Growth (Q YOY) | 48.38% | |||
| Earnings Growth (Q YOY) | 114.70% | |||
| EPS Diluted (TTM) | 0.35 | |||
| EPS Diluted Growth (Q YOY) | 101.28% | |||
| Balance Sheet | BIOX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 41.44M | |||
| Cash Per Share (Q) | $0.65 | |||
| Total Current Assets (Q) | 391.99M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 335.26M | |||
| Current Ratio (Q) | 1.237 | |||
| Book Value Per Share (Q) | $4.78 | |||
| Total Assets (Q) | 819.52M | |||
| Total Current Liabilities (Q) | 316.81M | |||
| Total Debt (Q) | 236.64M | |||
| Total Liabilities (Q) | 484.26M | |||
| Total Common Equity (Q) | 300.54M | |||
| Cash Flow | BIOX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -33.57M | |||
| Cash from Financing (TTM) | -33.67M | |||
| Net Change in Cash (TTM) | -44.15M | |||
| Levered Free Cash Flow (TTM) | 11.71M | |||
| Cash from Operations (TTM) | 29.61M | |||
